177 related articles for article (PubMed ID: 38481282)
21. Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia.
Papakonstantinou N; Ntoufa S; Tsagiopoulou M; Moysiadis T; Bhoi S; Malousi A; Psomopoulos F; Mansouri L; Laidou S; Papazoglou D; Gounari M; Pasentsis K; Plevova K; Kuci-Emruli V; Duran-Ferrer M; Davis Z; Ek S; Rossi D; Gaidano G; Ritgen M; Oscier D; Stavroyianni N; Pospisilova S; Davi F; Ghia P; Hadzidimitriou A; Belessi C; Martin-Subero JI; Pott C; Rosenquist R; Stamatopoulos K
Int J Cancer; 2019 Jun; 144(11):2695-2706. PubMed ID: 30447004
[TBL] [Abstract][Full Text] [Related]
22. High Expression of PDLIM2 Predicts a Poor Prognosis in Prostate Cancer and Is Correlated with Epithelial-Mesenchymal Transition and Immune Cell Infiltration.
Piao S; Zheng L; Zheng H; Zhou M; Feng Q; Zhou S; Ke M; Yang H; Wang X
J Immunol Res; 2022; 2022():2922832. PubMed ID: 35707002
[TBL] [Abstract][Full Text] [Related]
23. TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185.
Qiu F; Xiong JP; Deng J; Xiang XJ
Int J Clin Exp Pathol; 2015; 8(5):5053-61. PubMed ID: 26191199
[TBL] [Abstract][Full Text] [Related]
24. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
Linn DE; Bronson RT; Li Z
PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
[TBL] [Abstract][Full Text] [Related]
25. TRIM29 regulates the SETBP1/SET/PP2A axis via transcription factor VEZF1 to promote progression of ovarian cancer.
Qiao HY; Zhang Q; Wang JM; Jiang JY; Huyan LY; Yan J; Li C; Wang HQ
Cancer Lett; 2022 Mar; 529():85-99. PubMed ID: 34973391
[TBL] [Abstract][Full Text] [Related]
26. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions.
Cerveira N; Ribeiro FR; Peixoto A; Costa V; Henrique R; Jerónimo C; Teixeira MR
Neoplasia; 2006 Oct; 8(10):826-32. PubMed ID: 17032499
[TBL] [Abstract][Full Text] [Related]
27. Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma.
Aubry MC; Roden A; Murphy SJ; Vasmatzis G; Johnson SH; Harris FR; Halling G; Knudson RA; Ketterling RP; Feldman AL
Mod Pathol; 2015 Mar; 28(3):359-66. PubMed ID: 25189640
[TBL] [Abstract][Full Text] [Related]
28. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
[TBL] [Abstract][Full Text] [Related]
29. TRIM29 overexpression is associated with poor prognosis and promotes tumor progression by activating Wnt/β-catenin pathway in cervical cancer.
Xu R; Hu J; Zhang T; Jiang C; Wang HY
Oncotarget; 2016 May; 7(19):28579-91. PubMed ID: 27081037
[TBL] [Abstract][Full Text] [Related]
30. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.
Börno ST; Fischer A; Kerick M; Fälth M; Laible M; Brase JC; Kuner R; Dahl A; Grimm C; Sayanjali B; Isau M; Röhr C; Wunderlich A; Timmermann B; Claus R; Plass C; Graefen M; Simon R; Demichelis F; Rubin MA; Sauter G; Schlomm T; Sültmann H; Lehrach H; Schweiger MR
Cancer Discov; 2012 Nov; 2(11):1024-35. PubMed ID: 22930729
[TBL] [Abstract][Full Text] [Related]
31. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer.
Thangapazham R; Saenz F; Katta S; Mohamed AA; Tan SH; Petrovics G; Srivastava S; Dobi A
BMC Cancer; 2014 Jan; 14():16. PubMed ID: 24418414
[TBL] [Abstract][Full Text] [Related]
32. TRIM29 promotes progression of thyroid carcinoma via activating P13K/AKT signaling pathway.
Xu J; Li Z; Su Q; Zhao J; Ma J
Oncol Rep; 2017 Mar; 37(3):1555-1564. PubMed ID: 28098872
[TBL] [Abstract][Full Text] [Related]
33. Bioinformatics Analysis of GFAP as a Potential Key Regulator in Different Immune Phenotypes of Prostate Cancer.
Yao W; Li X; Jia Z; Gu C; Jin Z; Wang J; Yuan B; Yang J
Biomed Res Int; 2021; 2021():1466255. PubMed ID: 34222466
[TBL] [Abstract][Full Text] [Related]
34. Tissue specific DNA methylation in normal human breast epithelium and in breast cancer.
Avraham A; Cho SS; Uhlmann R; Polak ML; Sandbank J; Karni T; Pappo I; Halperin R; Vaknin Z; Sella A; Sukumar S; Evron E
PLoS One; 2014; 9(3):e91805. PubMed ID: 24651077
[TBL] [Abstract][Full Text] [Related]
35. TRIM29 prevents hepatocellular carcinoma progression by inhibiting Wnt/β-catenin signaling pathway.
Xu M; Hu J; Zhou B; Zhong Y; Lin N; Xu R
Acta Biochim Biophys Sin (Shanghai); 2019 Jan; 51(1):68-77. PubMed ID: 30566565
[TBL] [Abstract][Full Text] [Related]
36. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.
Sandoval GJ; Pulice JL; Pakula H; Schenone M; Takeda DY; Pop M; Boulay G; Williamson KE; McBride MJ; Pan J; St Pierre R; Hartman E; Garraway LA; Carr SA; Rivera MN; Li Z; Ronco L; Hahn WC; Kadoch C
Mol Cell; 2018 Aug; 71(4):554-566.e7. PubMed ID: 30078722
[TBL] [Abstract][Full Text] [Related]
37. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
38. Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression.
Jiang Y; Jiang YY; Xie JJ; Mayakonda A; Hazawa M; Chen L; Xiao JF; Li CQ; Huang ML; Ding LW; Sun QY; Xu L; Kanojia D; Jeitany M; Deng JW; Liao LD; Soukiasian HJ; Berman BP; Hao JJ; Xu LY; Li EM; Wang MR; Bi XG; Lin DC; Koeffler HP
Nat Commun; 2018 Sep; 9(1):3619. PubMed ID: 30190462
[TBL] [Abstract][Full Text] [Related]
39. Unveiling the m6A Methylation Regulator Links between Prostate Cancer and Periodontitis by Transcriptomic Analysis.
Ding D; Liu G; Gao J; Cao M
Dis Markers; 2022; 2022():4030046. PubMed ID: 36133437
[TBL] [Abstract][Full Text] [Related]
40. Identification of key DNA methylation-driven genes in prostate adenocarcinoma: an integrative analysis of TCGA methylation data.
Xu N; Wu YP; Ke ZB; Liang YC; Cai H; Su WT; Tao X; Chen SH; Zheng QS; Wei Y; Xue XY
J Transl Med; 2019 Sep; 17(1):311. PubMed ID: 31533842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
